Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 275,529,376
  • Shares Outstanding, K 2,482,023
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 22,392 M
  • EBITDA $ 26,891 M
  • 60-Month Beta 0.29
  • Price/Sales 4.35
  • Price/Cash Flow 11.44
  • Price/Book 5.21

Options Overview Details

View History
  • Implied Volatility 27.54% (-1.43%)
  • Historical Volatility 20.64%
  • IV Percentile 31%
  • IV Rank 18.49%
  • IV High 53.48% on 04/10/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 7) 2.37 (2.14%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 47,624
  • Volume Avg (30-Day) 38,776
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 712,736
  • Open Int (30-Day) 675,331
  • Expected Range 108.60 to 113.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.07
  • Number of Estimates 6
  • High Estimate 2.16
  • Low Estimate 1.98
  • Prior Year 1.72
  • Growth Rate Est. (year over year) +20.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.79 +14.65%
on 12/16/25
112.90 -1.71%
on 01/08/26
+10.71 (+10.68%)
since 12/15/25
3-Month
82.01 +35.31%
on 11/04/25
112.90 -1.71%
on 01/08/26
+26.86 (+31.93%)
since 10/15/25
52-Week
73.31 +51.37%
on 05/15/25
112.90 -1.71%
on 01/08/26
+10.88 (+10.87%)
since 01/15/25

Most Recent Stories

More News
1 Momentum Stock Worth Your Attention and 2 Facing Headwinds

1 Momentum Stock Worth Your Attention and 2 Facing Headwinds

MRK : 110.97 (-0.04%)
NPO : 241.74 (+5.25%)
GATX : 177.02 (-0.04%)
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 81.36 (+2.56%)
VHT : 291.96 (-0.53%)
NVO : 57.12 (-3.04%)
JNJ : 219.57 (+0.47%)
MRK : 110.97 (-0.04%)
HCA : 483.80 (+1.04%)
ABBV : 216.75 (-2.32%)
UNH : 338.96 (+1.19%)
ELV : 381.93 (+2.44%)
PFE : 25.89 (+1.21%)
TSLA : 438.57 (-0.14%)
LLY : 1,032.97 (-3.76%)
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEXâ„¢ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Third Phase 3 trial in Merck’s KANDLELIT clinical development program, which is investigating calderasib in KRAS G12C-mutant cancers across multiple tumor types and treatment settings...

MRK : 110.97 (-0.04%)
Merck to Complete Acquisition of Cidara Therapeutics

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common...

MRK : 110.97 (-0.04%)
CDTX : 221.38 (+0.03%)
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 sales and earnings conference call with institutional investors and analysts at...

MRK : 110.97 (-0.04%)
Merck & Co.'s Q4 2025 Earnings: What to Expect

Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

XLV : 156.96 (-0.57%)
$SPX : 6,944.47 (+0.26%)
MRK : 110.97 (-0.04%)
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president,...

MRK : 110.97 (-0.04%)
Dogs of the Dow Enhanced Income Strategy with Covered Calls

The Dogs of the Dow has long been a simple, rules-based approach to equity investing, built around owning the highest-yielding stocks in the Dow Jones Industrial Average. Each year, investors rotate into...

VZ : 39.36 (-1.18%)
CVX : 166.16 (-0.65%)
KO : 70.48 (-1.34%)
MRK : 110.97 (-0.04%)
PG : 144.63 (-1.18%)
JNJ : 219.57 (+0.47%)
NKE : 64.59 (-1.49%)
HD : 379.16 (+0.85%)
AMGN : 330.03 (+0.32%)
UNH : 338.96 (+1.19%)
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient...

MRK : 110.97 (-0.04%)
Stocks Settle Higher on Upbeat Tech Outlook and Cooling Inflation

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +1.51%. December...

AMAT : 319.08 (+5.69%)
GOOGL : 332.78 (-0.91%)
CNK : 24.46 (+1.58%)
AAPL : 258.21 (-0.67%)
SNDK : 409.24 (+5.53%)
MRK : 110.97 (-0.04%)
$IUXX : 25,547.08 (+0.32%)
ASML : 1,331.60 (+5.37%)
DJT : 13.66 (-2.29%)
ZNH26 : 112-050 (-0.06%)
MSFT : 456.66 (-0.59%)
TSLA : 438.57 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 115.35
2nd Resistance Point 113.46
1st Resistance Point 112.22
Last Price 110.97
1st Support Level 109.09
2nd Support Level 107.20
3rd Support Level 105.96

See More

52-Week High 112.90
Last Price 110.97
Fibonacci 61.8% 97.78
Fibonacci 50% 93.10
Fibonacci 38.2% 88.43
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar